-
Can GenAI for Literature Reviews Ever Be Trusted? A Pragmatic Approach That’s Ethically Designed and Purpose-built for HEOR Professionals
Oct 3, 2024, 16:38 PM -
Transferability of Data and Methods to Central and Eastern Europe
Sep 19, 2024, 12:53 PM -
Moving Toward Universal Health Coverage in Africa: The Role of HTA
Aug 22, 2024, 14:15 PM -
The Role of RWE for Devices and Diagnostic Market Access in Europe
Jul 9, 2024, 12:44 PM -
ISPOR Top 10 HEOR Trends - What Are the Key Themes for 2024-2025?
Jun 12, 2024, 13:19 PM -
Overcoming the Barriers of Open-Source Modeling
Jun 11, 2024, 14:37 PM -
Assessing the Fiscal Burden of Obesity Using a Public Economic Framework
May 30, 2024, 13:20 PM -
Are Clinical Outcome Assessments Sufficiently Valued?
May 29, 2024, 15:21 PM -
The Global Socioeconomic Impact of Rare Diseases: A Call for Action
May 22, 2024, 12:35 PM -
Revolutionizing Systematic Reviews: Harnessing the Power of AI
May 21, 2024, 10:54 AM -
Revolutionizing Clinical Trials: Harnessing Real-World Evidence to Drive Diversity and Clinical Implementation
Apr 11, 2024, 14:15 PM -
Measuring the Indirect Costs Driving Financial Toxicity in Oncology
Apr 8, 2024, 16:02 PM -
Beyond the Boundaries of RCT Data: Connecting Trials to the Real-World
Apr 3, 2024, 15:29 PM -
Measuring Value in Oncology: Are We Keeping Pace with Science?
Mar 11, 2024, 14:21 PM -
Patient WAIT Survey Findings Across 8 LATAM Countries
Feb 19, 2024, 11:34 AM -
Digital Technologies for Health Systems: The African Experience
Dec 8, 2023, 14:25 PM -
Tokenization in Clinical Trials: Benefits and End-to-End Enablement
Dec 6, 2023, 10:19 AM -
ISPOR Professional Competencies for HEOR Professionals
Nov 29, 2023, 09:54 AM -
Payer Views on Prescription Digital Therapeutics in the US and Canada
Oct 16, 2023, 11:17 AM -
How Does Biosimilar Availability Create Value for the Patient? A Conversation About Avenues to Widen Access to Biologics
Oct 11, 2023, 12:23 PM